2uzi: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Many disease-related processes occur via protein complexes that are, considered undruggable with small molecules. An example is RAS, which is, frequently mutated in cancer and contributes to initiation and maintenance, of the disease by constitutive signal transduction through protein, interaction with effector proteins, like PI3K, RAF and RALGDS. Such, protein interactions are therefore significant targets for therapy. We, describe a single immunoglobulin variable region domain that specifically, binds to activated GTP-bound RAS and prevents RAS-dependent tumorigenesis, in a mouse model. The crystal structure of the immunoglobulin-RAS complex, shows that the variable region competitively binds to the conformationally, variant regions of RAS, where its signalling effector molecules ... | Many disease-related processes occur via protein complexes that are, considered undruggable with small molecules. An example is RAS, which is, frequently mutated in cancer and contributes to initiation and maintenance, of the disease by constitutive signal transduction through protein, interaction with effector proteins, like PI3K, RAF and RALGDS. Such, protein interactions are therefore significant targets for therapy. We, describe a single immunoglobulin variable region domain that specifically, binds to activated GTP-bound RAS and prevents RAS-dependent tumorigenesis, in a mouse model. The crystal structure of the immunoglobulin-RAS complex, shows that the variable region competitively binds to the conformationally, variant regions of RAS, where its signalling effector molecules interact., This allows the plasma membrane targeted single domain intrabody to, inhibit signalling by mutant RAS. This mode of action is a novel advance, to directly interfere with oncogenic RAS function in human cancer and, shows a universally applicable approach to develop macromolecules to, combat cancer. In addition, this method illustrates a general means for, interfering with protein interactions that are commonly considered, intractable as conventional drug targets. | ||
==About this Structure== | ==About this Structure== | ||
2UZI is a | 2UZI is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with ZN, MG and GTP as [http://en.wikipedia.org/wiki/ligands ligands]. Structure known Active Site: AC1. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2UZI OCA]. | ||
==Reference== | ==Reference== | ||
| Line 38: | Line 38: | ||
[[Category: signaling protein/immune system]] | [[Category: signaling protein/immune system]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 5 13:10:01 2007'' | ||
Revision as of 14:04, 5 November 2007
|
CRYSTAL STRUCTURE OF HRAS(G12V)- ANTI-RAS FV COMPLEX
OverviewOverview
Many disease-related processes occur via protein complexes that are, considered undruggable with small molecules. An example is RAS, which is, frequently mutated in cancer and contributes to initiation and maintenance, of the disease by constitutive signal transduction through protein, interaction with effector proteins, like PI3K, RAF and RALGDS. Such, protein interactions are therefore significant targets for therapy. We, describe a single immunoglobulin variable region domain that specifically, binds to activated GTP-bound RAS and prevents RAS-dependent tumorigenesis, in a mouse model. The crystal structure of the immunoglobulin-RAS complex, shows that the variable region competitively binds to the conformationally, variant regions of RAS, where its signalling effector molecules interact., This allows the plasma membrane targeted single domain intrabody to, inhibit signalling by mutant RAS. This mode of action is a novel advance, to directly interfere with oncogenic RAS function in human cancer and, shows a universally applicable approach to develop macromolecules to, combat cancer. In addition, this method illustrates a general means for, interfering with protein interactions that are commonly considered, intractable as conventional drug targets.
About this StructureAbout this Structure
2UZI is a Protein complex structure of sequences from Homo sapiens with ZN, MG and GTP as ligands. Structure known Active Site: AC1. Full crystallographic information is available from OCA.
ReferenceReference
Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS., Tanaka T, Williams RL, Rabbitts TH, EMBO J. 2007 Jul 11;26(13):3250-9. Epub 2007 Jun 14. PMID:17568777
Page seeded by OCA on Mon Nov 5 13:10:01 2007
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Pages with broken file links
- Homo sapiens
- Protein complex
- Rabbitts, T.H.
- Tanaka, T.
- Williams, R.L.
- GTP
- MG
- ZN
- Antibody
- Cancer therapy
- Disease mutation
- Golgi apparatus
- Gtp-binding
- Immunoglobulin domain
- Intrabody
- Lipoprotein
- Membrane
- Methylation
- Nucleotide-binding
- Oncogene
- Palmitate
- Prenylation
- Proto-oncogene
- Signal transduction
- Signaling protein/immune system